WO2023034408A1 - Chimeric antigen receptor (car) t cell therapy platform - Google Patents

Chimeric antigen receptor (car) t cell therapy platform Download PDF

Info

Publication number
WO2023034408A1
WO2023034408A1 PCT/US2022/042193 US2022042193W WO2023034408A1 WO 2023034408 A1 WO2023034408 A1 WO 2023034408A1 US 2022042193 W US2022042193 W US 2022042193W WO 2023034408 A1 WO2023034408 A1 WO 2023034408A1
Authority
WO
WIPO (PCT)
Prior art keywords
ada
cell
cells
virus
oncolytic virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2022/042193
Other languages
English (en)
French (fr)
Other versions
WO2023034408A4 (en
Inventor
Xiaotong Song
Ruoning Wang
Abhijit Sarkar
Yue Hu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Texas A&M University System
Nationwide Children's Hospital
Original Assignee
Texas A&M University System
Nationwide Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Texas A&M University System, Nationwide Children's Hospital filed Critical Texas A&M University System
Priority to EP22865500.7A priority Critical patent/EP4396341A4/en
Priority to US18/686,868 priority patent/US20240350546A1/en
Priority to KR1020247010529A priority patent/KR20240050428A/ko
Priority to CN202280072744.7A priority patent/CN118265784A/zh
Priority to JP2024513689A priority patent/JP2024533109A/ja
Publication of WO2023034408A1 publication Critical patent/WO2023034408A1/en
Publication of WO2023034408A4 publication Critical patent/WO2023034408A4/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4261—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/485—Exopeptidases (3.4.11-3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/14—Dipeptidyl-peptidases and tripeptidyl-peptidases (3.4.14)
    • C12Y304/14005—Dipeptidyl-peptidase IV (3.4.14.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
    • C12Y305/04004—Adenosine deaminase (3.5.4.4)

Definitions

  • CAR T cell therapy has represented an exciting breakthrough in the treatment of patients with hematologic malignancies leading to the FDA approval of CAR T cell therapies for Acute Lymphoblastic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), lymphoma, and Multiple Myeloma (MM).
  • ALL Acute Lymphoblastic Leukemia
  • CLL Chronic Lymphocytic Leukemia
  • MM Multiple Myeloma
  • the suboptimal efficacy of current CAR-T cell therapies for solid tumors is most likely due to i) immunosuppressive solid tumor microenvironment, ii) suboptimal T cell persistence in vivo post cell injection, and iii) suboptimal CAR-T cell trafficking in vivo.
  • TME nutrient-poor tumor microenvironment
  • Inosine is a common component of food, and studies demonstrate that inosine has neuroprotective, cardioprotective and immunomodulatory effects. Although inosine has a weak binding affinity with adenosine receptor, earlier studies have shown that inosine produces anti-inflammatory effects related to the activation of adenosine receptors, mainly the A2a and A3 receptor whose activation can contribute to the reduction of pro- inflammatory cytokines, and tissue protective effects from endotoxin-induced and 2,4,6- trinitrobenzene sulfonic acid (TNBS)-induced inflammation.
  • TNBS 2,4,6- trinitrobenzene sulfonic acid
  • inosine is a key bacterial-derived metabolite acting through T cell-specific A2AR signaling to promote Thl cell activation in a context-dependent manner. Specifically, in the presence of IFN-gamma, inosine strongly boosted Thl differentiation of native T cells, whereas in the absence of IFN-gamma, inosine inhibited Thl differentiation.
  • inosine can amplify the antitumor efficacy of T-cell therapy or immune checkpoint inhibitors.
  • an independent study has shown that inosine can strongly sensitize tumor cells to the cytolytic effect of immune cells by enhancing tumor immunogenicity.
  • Adenosine deaminase (ADA) is known to have anti-tumor activity.
  • ADA adenosine deaminase 2
  • PEG-ADA2 Addenosine deaminase 2
  • ADA half-life is only several hours long, and PEG conjugation does not significantly increase the protein’s half-life. Therefore, in order for ADA to serve as an effective cancer therapy, the half-life must be improved.
  • ADA decreases the level of adenosine, an immunosuppressive metabolite, by irreversibly converting it to inosine.
  • ADA is a key enzyme of purine metabolism required for the breakdown of adenosine from food and for the turnover of nucleic acids in tissues.
  • ADA1 and ADA2 are two ADA isoenzymes in humans.
  • ADA1 is primarily involved in intracellular activity in most body cells, particularly lymphocytes.
  • ADA1 deficiency in humans causes severe combined immune deficiency (SCID).
  • ADA2 is the predominant form present in human blood plasma.
  • ADA1 and ADA2 might play different roles in regulating immune responses independent of their ADA activity.
  • ADA1 has co- stimulatory effects on T cell-mediated immunity by binding to Teffs and CTLs that express CD26.
  • ADA2 binds to neutrophils, CD16+ monocytes, NK cells, B cells and CD39+ Treg that do not express CD26.
  • PEGylated ADA2 inhibited tumor growth by targeting adenosine in an enzyme activity dependent manner and modulating immune responses.
  • ADA1 has a 100-fold higher affinity for adenosine than ADA2.
  • Adenosine signaling has emerged as a key immuno-metabolic checkpoint in tumors.
  • ATP or NAD+ accumulate within the TME and can generate adenosine by ecto- nucelotidases including CD39, CD73, CD38, CD203a, ALP and PAP53-61.
  • adenosine enables tumor cells to escape immune-surveillance by suppressing the function of multiple potentially protective immune cells including T cells, DCs, NK cells, macrophages and neutrophils, while enhancing the activity of immunosuppressive cells such as MDSCs and Tregs.
  • adenosine activates cancer associated fibroblasts and induces the formation of new blood vessels.
  • Oncolytic vaccinia viruses are an appealing addition to the current treatment options of solid tumors because of their safety and their potential to infect, replicate in, and lyse tumor cells.
  • intratumoral or intravenous injection of oncolytic vaccinia viruses was safe and can induce tumor lysis, the antitumor efficacy of the oncolytic vaccinia viruses is suboptimal and most tumors occurred. This is most likely due to the limited activation of antitumor T-cell responses within the tumor of oncolytic vaccinia virus and the immunosuppressive tumor environment. Therefore, an oncolytic vaccinia virus that 1) reverses immunosuppressive tumor microenvironment, and 2) effectively supports T-cell function, will overcome the current limitations of oncolytic vaccinia viruses.
  • T cells are able to control tumor growth and survival in cancer patients, both in early and late stages of the disease.
  • adoptive transfer of T cells has been demonstrated to effectively treat disseminated tumors including Hodgkin’s Lymphoma, nasopharyngeal carcinoma, neuroblastoma and melanoma.
  • tumor-specific T-cell responses are difficult to mount and sustain in cancer patients and are limited by numerous immune escape mechanisms of tumor cells selected during immunoediting. Therefore, it would be desirable to develop an alternative strategy to utilize T cells for cancer therapy with the ability of overcoming the immune escape mechanism of tumors.
  • the present application addresses the disadvantages that exist in current cancer therapies.
  • Methods and compositions for treating cancers using an engineered immune cells e.g., CAR-T cells, CAR-NK cells, CAR-NKT cells, macrophage
  • a recombinant oncolytic virus encoding a adenosine deaminase
  • the engineered immune cells or recombinant oncolytic virus encodes one or more other heterologous proteins.
  • the present application also provides methods and uses of the engineered immune cells or oncolytic virus for treating diseases and conditions, such as cancer, and in particular any disease or condition associated with elevated adenosine or other associate marker.
  • An embodiment of the claimed invention is directed to an engineered cell comprising a nucleotide sequence encoding an Adenosine deaminase (ADA).
  • the cell is T cell, natural killer cell, natural killer T cell, dendritic cell, macrophage, mesenchymal stem cell, and derivatives thereof.
  • An embodiment of the claimed invention is directed to a pharmaceutical composition comprising an engineered cell.
  • a further embodiment of the claimed invention is directed to a method of administering a pharmaceutical composition comprising an engineered cell to a patient in an amount effective for treatment of a cancer.
  • Another embodiment of the invention is directed to a recombinant oncolytic virus comprising a nucleotide sequence encoding an ADA, wherein the nucleotide sequence encoding the ADA is operably linked to a promoter.
  • An embodiment of the invention is directed to a recombinant protein comprising an amino acid sequence encoding an ADA.
  • FIG. 1 shows the designs of conjugated ADA used in embodiments of the invention
  • FIG. 2 shows a rationale for an CD26/ADA-CD3-scFv expressed CAR T cell therapy.
  • CAR T cells are engineered to express a tumor-specific CAR, a membrane CD26, and a secreted bispecific ADA-CD3-scFv.
  • CAR T cells 1) target and kill specific tumor cells; 2) stimulate CAR T cells by ADA-CD3-scFv (CD3-scFv anchors ADA to T cells since the binding affinity of CD3 and CD3-scFv is higher than that of ADA-CD26, while CD3-scFv itself can activate T cells), inducing CAR T cell activation and migration, 3) release CAR T cells from adenosine-mediated immune suppression; and 4) provide inosine as alternative carbon source for CAR T cells, and enhance the anti-tumor activity of CAR T cell therapy;
  • FIG. 3 shows the construction of an HER2-targeted CD26/ADA-CD3- scFv expressed CAR retroviral vector and an CD26/ADA-CD3-scFv expressed retroviral vector
  • FIG. 4 shows that Rv-CD26 transduced CAR T cells can resist the suppression of TGF-beta on CD26 expression, while CD26 expression of non-Rv-CD26- transduced CAR T cells were suppressed by TGF-beta;
  • FIGS. 5A and 5B show that Rv-CD26 transduced CAR T cells displayed enhanced migration capacity in a fluorescent migration assay (FIG. 5A) and a transwell migration assay (FIG. 5B);
  • FIG. 6 shows the mechanism of action of the ADA-CD3-scFv on the metabolic reprogrammed CAR-T cells: (A) CD3-scFv anchors ADA to T cells since CD3 and CD3-scFv has higher binding affinity than that of CD26-ADA, while CD3-scFv can directly activate T cells through CD3; (B) ADA engages CD26, co-stimulating CAR T cells; and (C) ADA converts ADO to INO, overcoming ADO-mediated immunosuppression on CAR T cells while providing INO as alternative energy resources for CAR T cell survival and proliferation;
  • FIGS. 7 A and 7B show the expression of ADA-CD3 (ADA-CD3- scFv) by the retroviral vector transduced HEK 293 T or Jurkat T cells: (FIG. 7 A) western blotting of ADA-CD3-scFv using monoclonal Ab against ADA in HEK 293 T cells that were transduced with retroviral vector expressing ADA-CD3-scFv with or without a human IL2 signal peptide compared to non-transduced HEK 293 T cells, and (FIG.
  • FIGS. 8A, 8B and 8C show the expression of ADA-CD3-scFv (ADA- CD3):
  • FIG. 8A ELISA measurement of ADA in the supernatant or cell lysate of Rv-ADA- CD3-IL2sp (signal peptide)-transduced, Rv-ADA-CD3 (no IL2 sp)-transduced or non- transduced HEK 293 T cells;
  • FIGS. 8A, 8B and 8C show the expression of ADA-CD3-scFv (ADA- CD3):
  • FIG. 8A ELISA measurement of ADA in the supernatant or cell lysate of Rv-ADA- CD3-IL2sp (signal peptide)-transduced, Rv-ADA-CD3 (no IL2 sp)-transduced or non- transduced HEK 293 T cells;
  • FIG. 8A ELISA measurement of ADA in the supernatant or
  • FIGS. 9A, 9B and 9C show the enzyme activity of ADA (ADA1) by ADA enzyme activity assay:
  • FIG. 9 A ADA enzyme activity assay of co-culture of Jurkat T cells and Rv-ADA-CD3 (with IL2sp)-transduced or non-transduced HEK 293 T cells (Top: original reads; Bottom: non-transduced HEK 293 T cell background reads were subtracted);
  • FIG. 9B ADA binding assay of Jurkat-Dual or Jurkat-Dual-CD26 T cell lines;
  • FIG. 9C ADA binding assay of Jurkat-NEFA or Jurkat-NFAT-CD26 T cells lines;
  • FIG. 10A shows T-cell activation using Jurkat NFAT reporter T cell line:
  • FIG. 10A Jurkat NFAT reporter T cells were added with the supernatant of or the Rv-ADA or Rv-ADA-CD3 transduced HEK 293 T cell for 6 hours and subjected to luciferase assay;
  • FIG. 10B Jurkat NFAT reporter T cells were added with the supernatant of or the Rv-ADA or Rv-ADA-CD3 transduced HEK 293 T cell for 24 hours and subjected to luciferase assay;
  • FIG. 10A Jurkat NFAT reporter T cells were added with the supernatant of or the Rv-ADA or Rv-ADA-CD3 transduced HEK 293 T cell for 24 hours and subjected to luciferase assay.
  • Jurkat NFAT reporter T cells were added with the supernatant of or the Rv-ADA-CD3 or Rv-ADA-CD3 (IL2sp) transduced HEK 293 T cell for 6 hours or 24 hours and subjected to luciferase assay; and (FIG. 10D) ADA-CD3 (IL2sp) expression level were calculated;
  • FIGS. 11 A, 11B, 11C, 11D and 11 E show the antitumor activity of ADA- CAR-T cells using in vitro LDH assay:
  • FIG. 11 A GPC3 CAR expression level of different groups of cells by flow analysis;
  • FIG. 11B, FIG. 11C, FIG.11 D and FIG.11 E LDH assay of groups of CAR T cells against GPC-positive HepG2 or Huh7 liver tumor cell lines;
  • FIGS. 12A, 12B, 12C and 12D show the results of an antitumor efficacy and toxicity study carried out in mice.
  • An embodiment of the invention is directed to an engineered CAR T cell that expresses a tumor-specific CAR and expresses ADA (FIG. 1 & 3).
  • the engineered CAR T cell 1) targets and kills tumor-antigen specific tumor cells; 2) CAR T cells are co- stimulated by ADA through CD26 signaling, 3) CAR T cells are released from adenosine- mediated immune suppression; and 4) inosine is provided as an alternative carbon source for CAR T cells, enhancing the anti- tumor activity of CAR T cell therapy.
  • FIG. 1 sets forth examples of ADA-CAR T cell conjugates.
  • ADA-CD3- scFv/CD26-MRCAR T cells that express a tumor Ag-specific CAR and ADA-CD3- scFv/CD26 complex enhance the anti-tumor activity of CAR T cell therapy through a series of mechanisms: i) CAR molecule targets and direct T cells to kill tumor Ag-positive tumor cells; ii) ADA/CD26 complex releases the adenosine-mediated immune suppression by providing inosine as carbon source for CAR T cells by converting adenosine to inosine in the TME; and iii) CD26 mediates CAR T cell trafficking and remain bound to T cell surface via ADA.
  • ADA-CD3-scFv/CD26-MRCAR T cell has the potential to overcome current limitations on CAR-T cell therapy against solid tumors.
  • the ADA-CD3-scFv/CD26-MRCAR in FIG. 3 contains the following components: a chimeric antigen receptor containing a tumor antigen (e.g., HER2, GPC3) specific scFv (small chain variable fragment), a spacer, hinge, transmembrane domain (e.g., CD28 and/or 4-1BBL), CD3 zeta domain; ADA-CD3-scFv bispecific fusion protein, and CD26. These components were linked with the 2A sequence, or expressed in separate viruses (e.g., retroviral vector, lentiviral vector). Ecto-ADA is critical for protecting T cells from adenosine-mediated immune suppression, while cell free ADA is not.
  • a tumor antigen e.g., HER2, GPC3
  • scFv small chain variable fragment
  • spacer e.g., CD28 and/or 4-1BBL
  • CD3 zeta domain e.g., CD28 and/or 4
  • Rv-ADA T cells can express ⁇ ng ADA/ml per 24 hours and the ADA expression by Rv-ADA T cells only increases by 20% compared to that of non-modified T cells.
  • ADA concentration in human breast tumor tissue, normal tissue, or serum is 16.4-47.7ug/g, 11.5ug/g, or 160- 242ng/ml respectively.
  • ADA-armed T cell therapy is significantly limited by the ADA expression level of T cells.
  • Anchoring ADA to the cell surface overcomes this limitation by engagement of CD26 on the surface of T cells.
  • the CAR comprises an amino acid sequence having at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID Nos: 1, 3, 5, 7, 9, 18, 20, 22, and 24. 10, 12, 14, and 162, 4, 6, 8, 9, 19, 21, 23, and 25 11, 13, 15, and 17
  • CD3-scFv engages with CD3 on the infused CAR-T cells or endogenous T cells by anchoring ADA on T cell surface and promoting ADA-CD26 engagement and activating T cells through CD3 signaling.
  • ADA engages with CD26, it activates the infused CAR-T cells or endogenous T cells.
  • ADA converts adenosine to inosine, overcoming adenosine-mediated immune suppression on CAR-T cells and providing inosine as alternative energy resources for CAR-T cells.
  • FIG. 3 also shows a vector that contains ADA-CD3-scFv bispecific fusion protein and CD26 only. This vector can be used together with a vector that expresses a CAR against any type of tumor antigens to transduce human T cells to produce MRCAR T cells.
  • a retroviral vector system is used to express a HER2-specific CAR, a membrane CD26 and a secreted ADA-CD3-scFv (FIG. 3).
  • a retroviral vector system was also used to express a membrane CD26 and a secreted ADA-CD3-scFv only (FIG. 3).
  • T cell codon optimization was used to enhance transgene expression of ADA in human T cells.
  • An optimized human IL2 signal peptide was added to express ADA by human T cells.
  • Human peripheral monocytes were activated by plate-bound CD3 and CD28 antibodies for 2 days followed by virus transduction. Expression and secretion of ADA1 by T cells was confirmed by western blotting (FIG.7) and ELISA (FIG. 8).
  • ADA expression effectively converted adenosine to inosine (FIG. 9).
  • ADA-CD3 expression effectively activated human T cells (FIG.10).
  • the in vitro LDH cytotoxicity assays showed that GPC3- specifici MR-CAR displayed enhanced cytotoxicity against GPC3-positive liver cancer cell lines such as HepG2 and Huh7 (FIG.11).
  • CD26 Overexpression of CD26 in CAR T cells is critical for CAR T cell therapy. As shown in FIG.4, in the presence of TGF-beta, the expression of CD26 on CAR T cells are reduced in 48 hours, suggesting the CD26 expression can be suppressed by tumor microenvironment. Rv-CD26 can restore the CD26 expression in CAR T cells. As shown in FIG.4, Rv-CD26 transduced T cells expressed CD26 at a higher level compared to non- modified T cells. In addition, Rv-CD26 transduced T cells resisted TGF-beta-mediated immunosuppression and retained the CD26 expression at high level.
  • a further embodiment of the invention is directed to an ADA-CAR T cell therapy in transplantable mouse tumor models.
  • the results show the efficacy and antitumor properties of a CAR T cell therapy model.
  • MR-CAR T cells displayed enhanced anti-tumor effects in two mouse models. In the first model, NSG mice were inoculated with 2x10 c6 Huh? HCC tumor cells on the right flank at day 0. At day 7, the Huh?
  • mice were treated through tail vein with PBS, 2x10 c6 GPC3-CAR T cells, or 2x10 c6 GPC3- ADA1-CD3-CD26-CAR (designated as GPC3-MR-CAR), followed by tumor monitoring with caliper (FIG. 12A) and body weight measurement (FIG. 12B).
  • NSG mice were inoculated with 2x10 c6 A549 NSCLC tumor cells on the right flank at day 0.
  • MR-CAR T cells showed enhanced anti-tumor activity.
  • MR- CAR T cells significantly inhibit tumor growth in both Huh? HCC and A549 NSCLC mouse models while native CAR T cells only moderately inhibit Huh? or A549 tumor growth.
  • body weight was observed in either Huh? HCC or A549 NSCLC mouse model, indicating MR-CAR T cells did not induce toxicity in the mouse models.
  • the promising results in the mouse models provide a good predictor of efficacy of the CAR T cell platform in human subjects.
  • Another embodiment of the invention is directed to an optimized ADA that displays enhanced ADA activity compared to native ADA.
  • the optimized ADA is an ADA-Fc fusion protein that significantly prolongs ADA’s half-life, and improves its antitumor activity (FIG.l).
  • the optimized ADA is an antibody conjugated ADA (FIG.l).
  • Another embodiment of the invention is directed to an engineered oncolytic virus that expresses ADA or ADA derivatives such as ADA-Fc (FIG.l).
  • the engineered oncolytic virus that expresses ADA will infect and replicate in the tumor cells, and expresses ADA or ADA-Fc that can convert ADO to INO within tumor tissues, enhancing the antitumor efficacy of oncolytic virus.
  • the engineered oncolytic virus comprises an amino acid sequence having at least 70%, or at least 75%, or at least 80%, or at least 85%, or at least 90%, or at least 95%, or 100% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NOS: 5, 7, 9, 22, and 24.
  • CD28 no azide (NA)/low endotoxin (NE) (Pharmingen #33740D) - Img/ml
  • Dilute antibodies to a final concentration of 1 ug/ml in sterile water for example to coat 6 wells, add 3 uL of OKT3 and 3 uL of CD28 to 3 ml of sterile water) 2.
  • Add 0,5 ml ( 0.5 ug of antibody) of the antibody solution/well in the 24 well plate; seal it with parafilm
  • MR-CAR resisted TGF-beta mediated suppression on CD26 expression on CAR T cells and displayed greater migration capacity.
  • Rv-CD26 Rv-CD26
  • NT non-transduced T cells
  • the T cells were collected and stained with FTTC-conjugated human CD26 specific antibody.
  • the CD26 expression on T cells was then detected by flow analysis and showed as MFI (median fluorescence intensity).
  • Rv-CD26 transduced human T cells expressed CD26 at a higher level compared to non-transduced T cells (FIG.
  • Rv-CD26 vs NT MFI 1420 vs MFI 801) in the absence of TGF-beta.
  • TGF-beta 5ng/ml, lOng/ml, or 20ng/ml
  • CD26 expressions were decreased from MFI 801 to MFI 603, MFI 599, or MFI 626 individually, while CD26 expression on Rv-CD26-transduced T cells remain unchanged after 48 hours culture in the presence of TGF-beta (5ng/ml, lOng/ml, or 20ng/ml).
  • Bottom Chamber Add 235 ⁇ L of HER2-positive A549 cell supernatant (Chemoattractant) and 365 ⁇ L of serum free media to make it 600 ⁇ L to the bottom chamber for both NT (Non-Transduced) and CD26 Transduced HER2-CAR T cells.
  • Top Chamber Add 300 ⁇ L (5,00000 cells) of cell suspension (both NT and Rv-CD26 transduced) to each well of the top chamber.
  • Each cell type requires a separate Standard Curve. Prepare a Standard Curve by adding 50 ⁇ L cell suspension (1.8 x 10 6 cells/mL, 90,000 cells or make it 50000 with 1 x 10 6 cells/ml).
  • step A6 Add 550 ⁇ L of the mix to each well of bottom chamber (after 22hrs, step A6). It can be after 2Hrs or 4Hrs too depending on experiment design.
  • ADA-CD3-scFv expression by MR-CAR T cells is biologically functional
  • Rv-ADA- CD3-IL2sp was compared to a lentiviral vector that expresses an ADA CRISPR activation element.
  • Lv-ADA (CRISPR activation) virus or Rv-ADA-IL2sp were transduced into Jurkat T cells.
  • Lv-ADA (CRPSPR activation) transduced Jurkat T cells were selected by puromycin.
  • ADA expression was measured by western blotting using anti-ADA mAb at 7, 14, or 18 days of T cell culture.
  • FIG.7B Rv-ADAl-IL2sp expressed ADA at a higher level compared to Lenti-ADA activation.
  • ADA-CD3(scFv) The secretion of ADA-CD3(scFv) by MRCAR T cells were measured by ELISA against human ADA.
  • ADA in the supernatant or cell lysate of Rv-ADA-CD3-IL2sp (signal peptide)-transduced, Rv-ADA-CD3 (no IL2 sp)-transduced or non-transduced (NT) HEK 293 T cells were measured by ELISA.
  • T cells were co-cultured with Jurkat T cells to mimic a stress condition for cell culture
  • ADA-CD3-IL2sp transduced Jurkat T cells or CD26-Jurkat T cells were cultured for 24 hours and stained with PE-conjugated mAb against ADA and subjected to flow analysis of ADA expression.
  • ADA level on Rv-ADA-CD3-transduced Jurkat T cells was higher than that of Jurkat T cells, indicating CD3-scFv anchored ADA-CD3 on the surface of Jurkat T cells.
  • ADA-CD3 has high binding affinity with T cells and will engage on the surface of the T cells
  • the T cells were directly used to measure the ADA-CD3’s enzyme activity.
  • HEK 293 T cells were transduced with Rv-ADA-CD3 and seeded in 96 well plate at different density for overnight. After 24 hours, the cells were counted, and cell density was shown in FIG.9A. Then same amount of Jurkat T cells was added to the cell culture for 6 hours. The cell culture medium was removed, and the cells were directly subjected to ADA activity assay.
  • Rv-ADA-CD3 resulted in higher enzyme activity of converting ADO to INO at cell culture density of 10e5/well or 5xl0e5/well compared to control group, indicating the ADA secretion is stress condition mediated (left: original reads; right: non- transduced HEK 293 T cell background reads were subtracted).
  • ADA membrane binding efficiency was calculated using Rv-ADA-CD3-293T/CD26- Jurkat T as maximum and 293T/JurkatT W/O CD26 as background.
  • the results showed that the secreted ADA-CD3 engaged with both Jurkat-Dual and CD26- Jurkat-Dual (FIG. 9B) or Jurkat-NFAT and CD26- Jurkat-NFAT (FIG. 9C) completely, while secreted ADA (without CD3-scFv) only engaged with CD26- Jurkat-Dual (FIG. 9B) or CD26- Jurkat-NFAT (FIG. 9C) at 40% efficacy of secreted ADA-CD3.
  • ADA-CD3 improved engagement of ADA
  • ADA-CD3 ADA-CD3
  • ADA1- CD3 ADA1- CD3
  • FIG. 10A and 10B Rv-ADA (ADA1) or Rv-ADA-CD3 (ADA1- CD3) was transduced into 293 T cells.
  • 293 T cell culture medium (supernatant) or 293 T cells were added to the culture of NFAT-luciferase Jurkat reporter cell line. The cells were cultured for 6 hours (FIG. 10A) or 24 hours (FIG. 10B), and then cell culture medium were collected and subjected to luciferase assay.
  • ADA-CD3 (IL2sp) expression level were calculated as shown in FIG. 10D.
  • Rv-ADA-CD3 or Rv-ADA-CD3- IL2sp can induce ADA-CD3 expression at 0.3 ug/ml or >0.5ug/ml at 24 hours individually.
  • Dav 1 In 96 well U-bottom cell culture plate, tumor cells (lxl0e4) were co-cultured with effector cells CAR-T and NT-T (non-transduced T cells as negative control) in 200ul DMEM medium at a gradient E:T ratio as below for 4 h. Maximum load (positive control) well will be added with 20 ul of lysis buffer and culture for 30 minutes.
  • LDH lactate dehydrogenase
  • FIG. 11 the CAR T cells were co-cultured with HepG2 or Huh? liver cancer cells and subjected to LDH assay as above.
  • FIG.1 IB and FIG.11C showed that, at 4 hours of co-culture, MR-CAR (GPC3-ADA1-CD3-CD26) T cells displayed enhanced cytotoxicity against HepG2 (FIG.1 IB) or Huh? (FIG.l 1C) at E:T ratio of 20: 1 compared to that of GPC3-CAR T cells, while no significant difference were observed at E:T ration of 1:1. This is likely due to that the expression and secretion of ADA-CD3 (scFv) needs time.
  • MR-CAR displayed a significantly enhanced cytotoxicity against HepG2 (FIG.11D) or Huh? (FIG.11E) at either 18 hours or 24 hours of co-culture of MR-CAR T cells and the tumor cells.
  • mice 6 weeks old NSG mice were purchased from lax laboratory, and each group has 5 mice.
  • groups of NSG mice were first subcutaneously inoculated with 2xl0e6 Huh? HCC tumor cells in 200ul medium on the right flank at day 0.
  • the Huh? tumor bearing mice were treated through tail vein with 200ul PBS, 2xl0e6 GPC3-CAR T cells in 200ul medium, or 2xl0e6 GPC3-ADA1-CD3-CD26-CAR T cells in 200ul medium (designated as GPC3- MR-CAR).
  • the mice were monitored every 2 or 3 days.
  • mice were first subcutaneously inoculated with 2xl0e6 A549 NSCLC tumor cells in 200ul medium on the right flank at day 0. At day 7, the A549 tumor bearing mice were treated through tail vein with 2xl0e6 HER2-CAR T cells, or 2xl0e6 HER2-ADA1- CD3-CD26-CAR T cells in 200ul medium (designated as HER2-MR-CAR) or no treatment as control (NT).
  • the tumor size and body weight were measured as described above.
  • MR-CAR T cells showed enhanced anti-tumor activity.
  • MR-CAR T cells significantly inhibit tumor growth in both Huh7 HCC or A549 NSCLC mouse models while original CAR T cells only moderately inhibit Huh7 or A549 tumor growth.
  • no significant difference in body weight was observed in both Huh7 HCC and A549 NSCLC mouse models, indicating MR-CAR T cells didn’t induce toxicity in these mouse models.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PCT/US2022/042193 2021-08-31 2022-08-31 Chimeric antigen receptor (car) t cell therapy platform Ceased WO2023034408A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP22865500.7A EP4396341A4 (en) 2021-08-31 2022-08-31 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY PLATFORM
US18/686,868 US20240350546A1 (en) 2021-08-31 2022-08-31 Chimeric antigen receptor (car) t cell therapy platform
KR1020247010529A KR20240050428A (ko) 2021-08-31 2022-08-31 키메라 항원 수용체(car) t 세포 요법 플랫폼
CN202280072744.7A CN118265784A (zh) 2021-08-31 2022-08-31 嵌合抗原受体(car)t细胞疗法平台
JP2024513689A JP2024533109A (ja) 2021-08-31 2022-08-31 キメラ抗原受容体(car)t細胞療法プラットフォーム

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163238927P 2021-08-31 2021-08-31
US63/238,927 2021-08-31
US202263355396P 2022-06-24 2022-06-24
US63/355,396 2022-06-24

Publications (2)

Publication Number Publication Date
WO2023034408A1 true WO2023034408A1 (en) 2023-03-09
WO2023034408A4 WO2023034408A4 (en) 2023-04-27

Family

ID=85411600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/042193 Ceased WO2023034408A1 (en) 2021-08-31 2022-08-31 Chimeric antigen receptor (car) t cell therapy platform

Country Status (5)

Country Link
US (1) US20240350546A1 (cg-RX-API-DMAC7.html)
EP (1) EP4396341A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024533109A (cg-RX-API-DMAC7.html)
KR (1) KR20240050428A (cg-RX-API-DMAC7.html)
WO (1) WO2023034408A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4395795A4 (en) * 2021-08-30 2025-07-09 Univ Leland Stanford Junior T CELLS HAVING CELL SURFACE EXPRESSION OF ADENOSINE DEAMINASE AND THEIR USES
WO2026035304A1 (en) * 2024-04-08 2026-02-12 Gemini Corp. Medical modeling architecture, intelligence and methods

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180216095A1 (en) * 2014-10-14 2018-08-02 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2020120982A2 (en) * 2018-12-14 2020-06-18 Autolus Limited Cell
WO2020168122A1 (en) * 2019-02-13 2020-08-20 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112672753B (zh) * 2018-07-09 2025-07-08 普瑞赛格恩公司 融合构建体及其使用方法
US20250134998A1 (en) * 2021-08-30 2025-05-01 The Board Of Trustees Of The Leland Stanford Junior University T cells with cell-surface expression of adenosine deaminase and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180216095A1 (en) * 2014-10-14 2018-08-02 Halozyme, Inc. Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
WO2020120982A2 (en) * 2018-12-14 2020-06-18 Autolus Limited Cell
WO2020168122A1 (en) * 2019-02-13 2020-08-20 Beam Therapeutics Inc. Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP4396341A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4395795A4 (en) * 2021-08-30 2025-07-09 Univ Leland Stanford Junior T CELLS HAVING CELL SURFACE EXPRESSION OF ADENOSINE DEAMINASE AND THEIR USES
WO2026035304A1 (en) * 2024-04-08 2026-02-12 Gemini Corp. Medical modeling architecture, intelligence and methods

Also Published As

Publication number Publication date
KR20240050428A (ko) 2024-04-18
EP4396341A4 (en) 2025-07-09
EP4396341A1 (en) 2024-07-10
WO2023034408A4 (en) 2023-04-27
JP2024533109A (ja) 2024-09-12
US20240350546A1 (en) 2024-10-24

Similar Documents

Publication Publication Date Title
JP7475088B2 (ja) ヒトメソセリンを特異的に認識する細胞表面分子、il-7、及びccl19を発現する免疫担当細胞
US10124028B2 (en) Oncolytic adenovirus encoding a B7 protein or active fragment
US20180369304A1 (en) Virus encoding an anti-tcr-complex antibody or fragment
JP6971986B2 (ja) 免疫療法の抗腫瘍活性を高めるための間葉系幹細胞
US20230257706A1 (en) T lymphocyte and use thereof
CN106544365B (zh) 一种人抗cd19嵌合抗原受体修饰的cik的制备方法及应用
JP2017515504A (ja) キメラ抗原受容体タンパク質をコードする核酸およびキメラ抗原受容体タンパク質を発現するtリンパ球
CN110330567A (zh) 双特异性嵌合抗原受体t细胞,其制备方法和应用
CN109666074B (zh) 一种趋化因子受体cxcr5的用途
US12479890B2 (en) Chimeric antigen receptor constructs and their use in CAR-T cells
WO2024221985A1 (zh) 靶向cll1的car-t细胞及其制备方法与应用
CN108409840A (zh) 抗cd123单链抗体及其组合的嵌合抗原受体和应用
WO2018145648A1 (zh) 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
WO2022127372A1 (zh) 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用
KR20250024838A (ko) Kras g12v 돌연변이 폴리펩티드를 표적화하는 t 세포 수용체 및 이의 용도
AU2019338226A1 (en) MR1 restricted T cell receptors for cancer immunotherapy
CN116004547A (zh) 一种辐照car-t细胞及其制备方法与应用
EP4396341A1 (en) Chimeric antigen receptor (car) t cell therapy platform
WO2025190422A1 (zh) 含有双表位嵌合抗原受体的融合蛋白及其修饰的car-t细胞
WO2025130934A1 (zh) 表达膜结合型il-15融合蛋白的工程化til及其应用
EP4400113A1 (en) Hypoxia-triggered artificial transcription factor and hypoxia-triggered transcription control system, and application thereof
CN117903318A (zh) 靶向cll1的car-nk细胞制备及其应用
CN116059329A (zh) 溶瘤病毒与car t细胞联合治疗血液肿瘤的方法
CN118265784A (zh) 嵌合抗原受体(car)t细胞疗法平台
CN113046320B (zh) 胞外段为Vδ1(GTM)Vγ4的CAR分子及表达该分子的CAR-T细胞及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 22865500

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2024513689

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 20247010529

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2022865500

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2022865500

Country of ref document: EP

Effective date: 20240402

WWE Wipo information: entry into national phase

Ref document number: 202280072744.7

Country of ref document: CN